An interim analysis of a phase II study using an epigenetic biomarker (CHFR methylation status) to personalize chemotherapy in patients with operable esophageal cancer.

Ronan J. Kelly, James G. Herman, Russell K. Hales et al.|Journal of Clinical Oncology|2014

Cited by 2